Compare Stocks: AGIO, IONS, ALKS, and GRAL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$31.72 +1.5%	$33.17	$22.24 ▼ $46.00	$1.87B	0.63	1.03 million shs	1.28 million shs
ALKS Alkermes	$41.65 -2.6%	$46.44	$27.00 ▼ $55.67	$7.17B	0.32	2.47 million shs	1.55 million shs
GRAL GRAIL	$137.28 -10.9%	$88.31	$41.50 ▼ $166.48	$6.88B	2.83	1.51 million shs	2.03 million shs
IONS Ionis Pharmaceuticals	$44.00 +1.1%	$53.46	$42.63 ▼ $86.74	$7.23B	0.38	4.60 million shs	2.19 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-1.73%	-6.49%	-5.59%	-28.99%	-22.84%
ALKS Alkermes	+2.42%	+6.50%	-7.25%	-22.56%	+37.67%
GRAL GRAIL	+7.55%	+16.17%	+91.78%	+123.99%	+135.09%
IONS Ionis Pharmaceuticals	-0.09%	-4.54%	-25.12%	-49.61%	-37.09%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$31.72 +1.5%	$33.17	$22.24 ▼ $46.00	$1.87B	0.63	1.03 million shs	1.28 million shs
ALKS Alkermes	$41.65 -2.6%	$46.44	$27.00 ▼ $55.67	$7.17B	0.32	2.47 million shs	1.55 million shs
GRAL GRAIL	$137.28 -10.9%	$88.31	$41.50 ▼ $166.48	$6.88B	2.83	1.51 million shs	2.03 million shs
IONS Ionis Pharmaceuticals	$44.00 +1.1%	$53.46	$42.63 ▼ $86.74	$7.23B	0.38	4.60 million shs	2.19 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	-1.73%	-6.49%	-5.59%	-28.99%	-22.84%
ALKS Alkermes	+2.42%	+6.50%	-7.25%	-22.56%	+37.67%
GRAL GRAIL	+7.55%	+16.17%	+91.78%	+123.99%	+135.09%
IONS Ionis Pharmaceuticals	-0.09%	-4.54%	-25.12%	-49.61%	-37.09%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.55	Moderate Buy	$41.75	31.62% Upside
ALKS Alkermes	2.74	Moderate Buy	$54.47	30.78% Upside
GRAL GRAIL	2.33	Hold	$102.70	-25.19% Downside
IONS Ionis Pharmaceuticals	2.73	Moderate Buy	$89.20	102.73% Upside

Current Analyst Ratings Breakdown

Latest AGIO, IONS, ALKS, and GRAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	GRAL GRAIL	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$105.00 ➝ $175.00
10/1/2026	GRAL GRAIL	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$75.00 ➝ $155.00
9/28/2026	GRAL GRAIL	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$80.00 ➝ $150.00
9/25/2026	GRAL GRAIL	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$65.00 ➝ $100.00
9/24/2026	GRAL GRAIL	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/24/2026	IONS Ionis Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$85.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$50.00
9/24/2026	ALKS Alkermes	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold	$50.00
9/24/2026	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$100.00
9/22/2026	ALKS Alkermes	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$56.00
9/22/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $61.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	35.05	N/A	N/A	$20.46 per share	1.55
ALKS Alkermes	$1.48B	4.73	$1.63 per share	25.54	$11.02 per share	3.78
GRAL GRAIL	$147.17M	41.67	N/A	N/A	$66.13 per share	2.08
IONS Ionis Pharmaceuticals	$944M	7.75	N/A	N/A	$3.02 per share	14.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-35.67%	-33.06%	10/29/2026 (Estimated)
ALKS Alkermes	$241.66M	$0.38	109.61	173.54	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/4/2026 (Estimated)

Latest AGIO, IONS, ALKS, and GRAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q3 2026	AGIO Agios Pharmaceuticals	-$1.21	N/A	N/A	N/A	$53.81 million	N/A
10/28/2026	Q3 2026	ALKS Alkermes	-$0.0781	N/A	N/A	N/A	$463.47 million	N/A
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	10.22	9.79
ALKS Alkermes	0.82	2.30	1.85
GRAL GRAIL	N/A	10.95	10.95
IONS Ionis Pharmaceuticals	3.07	7.89	7.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
ALKS Alkermes	95.21%
GRAL GRAIL	N/A
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
ALKS Alkermes	4.59%
GRAL GRAIL	1.83%
IONS Ionis Pharmaceuticals	1.81%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	540	59.70 million	56.48 million	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
GRAL GRAIL	910	44.67 million	43.85 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable

AGIO, IONS, ALKS, and GRAL Headlines

Recent News About These Companies

Ionis Pharmaceuticals (NASDAQ:IONS) Sets New 1-Year Low - Time to Sell?

October 5 at 11:01 AM | americanbankingnews.com

Ionis Pharmaceuticals (NASDAQ:IONS) Reaches New 52-Week Low - Should You Sell?

October 5 at 10:59 AM | marketbeat.com

Consensus price target for Ionis Pharmaceuticals rises 20.88% to MX$1,849.62

October 2, 2026 | msn.com

Critical Review: Alector (NASDAQ:ALEC) vs. Ionis Pharmaceuticals (NASDAQ:IONS)

October 1, 2026 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Rated "Moderate Buy" by Sell-Side Analysts

September 30, 2026 | americanbankingnews.com

4 RNA Therapeutics Stocks Leading the Next Wave of Innovation

September 28, 2026 | zacks.com

Reviewing Synlogic (NASDAQ:SYBX) & Ionis Pharmaceuticals (NASDAQ:IONS)

September 28, 2026 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for Ionis Pharmaceuticals (NASDAQ:IONS)

September 26, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: NanoViricides (NNVC) and Ionis Pharmaceuticals (IONS)

September 25, 2026 | theglobeandmail.com

Oppenheimer Sticks to Its Buy Rating for Ionis Pharmaceuticals (IONS)

September 25, 2026 | theglobeandmail.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Stock Has Average Price Target of $89.20 According to Brokerages

September 25, 2026 | marketbeat.com

Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide

September 24, 2026 | finance.yahoo.com

Canaccord Genuity Remains a Buy on Ionis Pharmaceuticals (IONS)

September 24, 2026 | theglobeandmail.com

Ionis Pharmaceuticals (NASDAQ:IONS) Receives "Buy" Rating from HC Wainwright

September 24, 2026 | marketbeat.com

Ionis Pharmaceuticals, Roche Say Kidney Disease Drug Candidate Meets Main Goal in Phase 3 Study

September 23, 2026 | finance.yahoo.com

Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23, 2026 | rutlandherald.comR

Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

September 23, 2026 | zacks.com

Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease

September 23, 2026 | benzinga.com

Ionis announces positive interim data from partner Roche's Phase 3 IMAgINATION study in IgA nephropathy (IgAN)

September 23, 2026 | businesswire.com

Ionis Pharmaceuticals, Inc. (IONS) Stock: Surges as Phase 3 ALS Trial Delivers Positive Results

September 22, 2026 | blockonomi.com

Ionis drug ulefnersen meets primary endpoint in FUS-ALS Phase 3 trial

September 22, 2026 | streetinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

AGIO, IONS, ALKS, and GRAL Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$31.72 +0.47 (+1.50%)

Closing price 04:00 PM Eastern

Extended Trading

$31.74 +0.02 (+0.05%)

As of 07:30 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Alkermes NASDAQ:ALKS

$41.65 -1.11 (-2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$41.65 0.00 (0.00%)

As of 07:30 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

GRAIL NASDAQ:GRAL

$137.28 -16.80 (-10.90%)

Closing price 04:00 PM Eastern

Extended Trading

$138.60 +1.32 (+0.97%)

As of 07:59 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

Ionis Pharmaceuticals NASDAQ:IONS

$44.00 +0.50 (+1.15%)

Closing price 04:00 PM Eastern

Extended Trading

$43.76 -0.24 (-0.56%)

As of 07:30 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGIO, IONS, ALKS, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGIO, IONS, ALKS, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGIO, IONS, ALKS, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGIO, IONS, ALKS, and GRAL Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Alkermes NASDAQ:ALKS

GRAIL NASDAQ:GRAL

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGIO, IONS, ALKS, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGIO, IONS, ALKS, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGIO, IONS, ALKS, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

AGIO, IONS, ALKS, and GRAL Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Alkermes NASDAQ:ALKS

GRAIL NASDAQ:GRAL

Ionis Pharmaceuticals NASDAQ:IONS

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools